Borhani Samira, Mozdarani Hossein, Babalui Somayyeh, Bakhshandeh Mohsen, Nosrati Hassan
Department of Radiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Iran J Med Sci. 2017 May;42(3):258-265.
Glioma is the most common primary brain tumor with poor prognosis. Temozolomide (TMZ) has been used with irradiation (IR) to treat gliomas. The aim of the present study was to evaluate the cytotoxic and radiosensitizing effect of TMZ when combined with high-dose and high-dose rate of gamma irradiation in vitro.
Two 'U87MG' cell lines and skin fibroblast were cultured and assigned to five groups for 24, 48, and 72 hours. The groups were namely, TMZ group (2000 μM/L), IR group (5 Gy), TMZ plus IR group, control group, and control solvent group. MTT assay was applied to evaluate cell viability. Data were analyzed with SPSS 21.0 software using one-way ANOVA and Kruskal-Wallis test. P<0.05 were considered statistically significant.
The slope of growth curve U87MG cells in semi-logarithmic scale was equal to 27.36±0.89 hours. The viability of cells was determined for different TMZ and IR treatment groups. In terms of cell viability, there were no significant differences between the control and control solvent groups (P=0.35) and between treated group by IR (5 Gy) alone and TMZ (2000 µM/ml) alone (P=0.15). Data obtained for the cell viability of combined TMZ plus IR in both cell lines compared to TMZ or IR treated group alone showed a significant difference (P=0.002).
The evaluation of cells viability showed that TMZ in combination with IR on glioma cells led to a significant radiosensitivity compared to IR alone.
胶质瘤是最常见的原发性脑肿瘤，预后较差。替莫唑胺（TMZ）已与放疗（IR）联合用于治疗胶质瘤。本研究的目的是在体外评估TMZ与高剂量率伽马射线联合使用时的细胞毒性和放射增敏作用。
培养两种“U87MG”细胞系和皮肤成纤维细胞，并将其分为五组，分别培养24、48和72小时。这些组分别为TMZ组（2000μM/L）、IR组（5 Gy）、TMZ加IR组、对照组和对照溶剂组。采用MTT法评估细胞活力。使用SPSS 21.0软件，通过单因素方差分析和Kruskal-Wallis检验对数据进行分析。P<0.05被认为具有统计学意义。
U87MG细胞在半对数尺度下生长曲线的斜率等于27.36±0.89小时。测定了不同TMZ和IR治疗组的细胞活力。在细胞活力方面，对照组和对照溶剂组之间（P=0.35）以及单独接受IR（5 Gy）治疗的组和单独接受TMZ（2000µM/ml）治疗的组之间（P=0.15）没有显著差异。与单独的TMZ或IR治疗组相比，两种细胞系中TMZ加IR联合治疗的细胞活力数据显示出显著差异（P=0.002）。
细胞活力评估表明，与单独使用IR相比，TMZ与IR联合对胶质瘤细胞具有显著的放射敏感性。
